Molly Taylor Rehkop, MS, CCC-SLP | |
108 N Chiefs Ave, Alma, MO 64001 | |
(660) 674-2236 | |
Not Available |
Full Name | Molly Taylor Rehkop |
---|---|
Gender | Female |
Speciality | Speech-language Pathologist |
Location | 108 N Chiefs Ave, Alma, Missouri |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1154822021 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
235Z00000X | Speech-language Pathologist | 2017000404 (Missouri) | Primary |
Mailing Address | Practice Location Address |
---|---|
Molly Taylor Rehkop, MS, CCC-SLP 4350 Nw Lobo Ct, Lees Summit, MO 64064-1418 Ph: () - | Molly Taylor Rehkop, MS, CCC-SLP 108 N Chiefs Ave, Alma, MO 64001 Ph: (660) 674-2236 |
News Archive
The National Heart, Lung, and Blood Institute of the National Institutes of Health has awarded Rinku Majumder, PhD, Associate Professor of Biochemistry & Molecular Biology at LSU Health New Orleans School of Medicine, a $2.5 million grant over four years to help reduce the high stroke risk to women with obesity who take estrogen-containing birth control pills.
Crafting a fragrance for detergents that leaves laundry smelling clean and fresh. Developing a room freshener, scented oil, or scented candle that whispers "cool spring air." Giving toothpaste or mouthwash a refreshing aftertaste that lingers and lingers.
An analysis of six tests that are used to measure platelet function and help gauge the effectiveness of antiplatelet drugs for patients undergoing a cardiac procedure such as a coronary stent implantation found that only three of the tests were associated with a modest ability to predict outcomes such as heart attack or death, according to a study in the February 24 issue of JAMA.
The University of Ottawa Heart Institute (UOHI) participated in the largest genetic study of Coronary Artery Disease (CAD) to date. Researchers from the CARDIoGRAMplusC4D Consortium report the identification of 15 genetic regions newly associated with the disease, bringing to 46 the number of regions associated with CAD risk.
A commonly-used HIV drug has been shown to kill-off the human papilloma virus (HPV) that leads to cervical cancer in a world-first clinical trial led by The University of Manchester with Kenyatta National Hospital in Nairobi.
› Verified 4 days ago